News

At the heart of the ADECA process that is used to maintain the QTdrugs List is the active and passive surveillance of data for the thousands of prescription drugs  available  in the United States. We analyze this constant stream of new data to keep robust, up-to-date profiles on each drug – profiles that include laboratory research, relevant adverse event reports to FDA, CYP 450 metabolic activity, drug interactions, drug label information and much more.

AZCERT's Scientific Review Committee has reviewed available evidence for Remdesivir, an antiviral drug used to treat COVID-19, and found that its use is associated with the development of QTc prolongation. This analysis failed to find compelling evidence for a risk of torsades de pointes (TdP) arrhythmia. Therefore, Remdesivir has been added to the QTdrugs List in the Possible Risk of TdP category. The Committee has also added Serdexmethylphenidate, a new prodrug of dexmethylphenidate used to treat ADHD, to the List of Drugs to Avoid (DTA List) in patients with congenital Long QT Syndrome because of its adrenaline-like properties.